Ciprofloxacin

Introduction Overview

Generic Name

ciprofloxacin

Brand Name

Cipro

Dosage Form

oral tablets, oral suspension, intravenous injection, otic suspension, extended-release tablets

Drug Class

Fluoroquinolones (Quinolones and fluoroquinolones class)

Pharmacokinetics

Absorption:
Ciprofloxacin is rapidly and well absorbed from the gastrointestinal tract after oral administration, with an average bioavailability of approximately 70%. Peak plasma concentrations are typically achieved within 1 to 2 hours following ingestion of immediate-release formulations. Absorption can be significantly reduced by concurrent administration of divalent or trivalent cation-containing compounds such as antacids (containing magnesium or aluminum), sucralfate, iron salts, or multivitamins containing zinc or calcium. Therefore, to avoid chelation and decreased absorption, ciprofloxacin dosing should be separated by at least 2 hours before or 6 hours after these agents. Food intake may slightly delay the time to peak concentration but does not significantly reduce overall bioavailability, allowing ciprofloxacin to be taken with or without food for patient convenience.

Distribution:
Following absorption, ciprofloxacin is widely distributed into body tissues and fluids, including lung, prostate, bone, and urinary tract tissues, achieving concentrations often exceeding plasma levels, which supports its efficacy in treating diverse infections. The volume of distribution (Vd) ranges from approximately 2 to 3 L/kg, indicating extensive tissue penetration. Ciprofloxacin exhibits moderate plasma protein binding (about 20-40%), predominantly to albumin, which facilitates free drug availability for antibacterial action. It crosses the blood-brain barrier to a limited extent but achieves therapeutic cerebrospinal fluid levels in cases of meningeal inflammation. Ciprofloxacin also concentrates in macrophages and neutrophils, which transport the drug to infection sites.

Metabolism:
Ciprofloxacin undergoes limited hepatic metabolism, with approximately 20-30% of the administered dose metabolized. The major metabolic pathway produces an inactive metabolite, desethylene ciprofloxacin. Cytochrome P450 enzymes are minimally involved in its biotransformation, leading to low potential for metabolic drug interactions. The metabolic stability of ciprofloxacin contributes to predictable pharmacokinetics across varied patient populations, including those with mild to moderate hepatic impairment.

Elimination:
The elimination of ciprofloxacin occurs primarily via renal excretion, accounting for approximately 40-50% of the administered dose as unchanged drug in the urine within 24 hours. The remainder is excreted via feces largely as metabolites. The elimination half-life ranges from 4 to 5 hours in patients with normal renal function, supporting twice-daily dosing regimens. In patients with significantly impaired renal function (creatinine clearance less than 30 mL/min), dosage adjustments or increased dosing intervals are recommended to prevent drug accumulation and toxicity. Ciprofloxacin also undergoes some biliary excretion. Adequate elimination ensures maintenance of effective plasma concentrations without significant accumulation in patients with normal organ function.

Dosage Forms

Available Dosage Forms:
- Oral tablet: 100 mg, 250 mg, 500 mg, and 750 mg immediate release
- Extended-release oral tablet: 500 mg and 1000 mg
- Oral suspension: 100 mg/5 mL and 250 mg/5 mL
- Intravenous injection: various concentrations for parenteral administration
- Otic suspension: combined formulations with hydrocortisone for ear infections

Dosages for Adults and Adolescents:
- Typical adult oral dosage ranges from 250 mg to 750 mg twice daily depending on infection severity and type.
- For urinary tract infections and lower respiratory tract infections, 250-500 mg every 12 hours is common.
- Severe infections such as osteomyelitis or anthrax exposure may require higher doses (e.g., 750 mg twice daily).
- Extended-release tablets are dosed once daily usually for uncomplicated infections.
- Duration varies from 3 days (e.g., uncomplicated UTI) to up to 14 days or longer for complicated infections.

Specific Patient Populations:
- Renal Impairment: Dose adjustment recommended for patients with creatinine clearance less than 30 mL/min; typically, dose frequency is decreased to prevent accumulation.
- Pediatric Use: Safety and efficacy not well established; use only if benefits outweigh risks.
- Geriatric Patients: May have increased risk for tendon disorders; dose adjustment not routinely required but careful monitoring is essential.
- Pregnancy and Lactation: Use only if clearly needed; breastfeeding discouraged during therapy and for 2 days after last dose.

Important Instructions:
- Oral suspension must be shaken well for 15 seconds before measuring dose.
- Dosing syringe or accurate measuring device should be used for suspension; do not administer suspension via feeding tube.
- Tablets can be taken with or without food, but avoid concurrent intake with dairy products or fortified juices alone because of chelation risk.
- Ensure adherence to prescribed dosing interval to prevent resistance development.

Mechanism Of Action

Ciprofloxacin exerts its antibacterial effect by inhibiting bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes critical to bacterial DNA replication, transcription, repair, and recombination. DNA gyrase introduces negative supercoils into DNA, which is essential for maintaining DNA topology during replication and transcription. By stabilizing the DNA-enzyme complex after DNA strand cleavage, ciprofloxacin prevents the relegation step, leading to accumulation of DNA breaks and bacterial cell death.

At the cellular level, ciprofloxacin penetrates gram-negative and some gram-positive bacteria efficiently, targeting DNA gyrase primarily in gram-negative species and topoisomerase IV in gram-positive species. This dual targeting increases its spectrum of action and helps reduce the emergence of resistance. The drug acts bactericidally, causing rapid bacterial cell death through inhibition of DNA replication processes.

Biochemically, ciprofloxacin forms a ternary complex with the enzyme and DNA, interfering with the breakage-reunion activity of the topoisomerases. This leads to arrested DNA synthesis and triggers the bacterial cell's SOS response, ultimately resulting in apoptosis-like death mechanisms. The fluoroquinolone moiety contributes to enhanced penetration and potent enzyme inhibition compared to earlier quinolones.

Clinically, ciprofloxacin’s mechanism explains its broad spectrum activity against many aerobic gram-negative bacilli, including Pseudomonas aeruginosa, and some gram-positive cocci. Its efficacy for urinary tract infections, respiratory infections, gastrointestinal infections, and certain systemic infections hinges on this enzymatic inhibition. Comparative studies indicate ciprofloxacin has higher potency and fewer side effects relative to older quinolones, though resistance development through mutations in gyrase or efflux pumps remains a clinical concern. Research continues on its molecular targets and overcoming resistance mechanisms to optimize therapy.

Pharmacological Actions

Inhibits bacterial DNA gyrase and topoisomerase IV enzymes, essential for DNA replication and cell division
Bactericidal activity against a broad spectrum of gram-negative and some gram-positive bacteria
Penetrates bacterial cells effectively, leading to rapid killing of susceptible pathogens
Extensive tissue distribution facilitates treatment of deep-seated infections
Blocks DNA supercoiling and replication, resulting in lethal double-strand DNA breaks
Active against aerobic bacteria, including Pseudomonas aeruginosa, E. coli, Salmonella, Shigella, and Neisseria species
Exhibits concentration-dependent killing properties
Demonstrates post-antibiotic effect, suppressing bacterial regrowth after plasma levels decline
Limited activity against anaerobic bacteria – used in combination when anaerobic coverage is needed
May alter bacterial SOS response pathways, contributing to bactericidal effects
Pharmacodynamic parameter best associated with efficacy is the ratio of AUC (area under curve) to MIC (minimum inhibitory concentration)
Possesses anti-biofilm activity against certain bacterial species
Can penetrate phagocytic cells, enhancing the killing of intracellular pathogens
Has low potential for cytochrome P450 mediated drug interactions
Resistance may develop due to point mutations in target enzymes or increased efflux

Therapeutic Or Clinical Uses

Treatment of complicated and uncomplicated urinary tract infections, including pyelonephritis
Management of lower respiratory tract infections such as pneumonia and bronchitis
Treatment of skin, soft tissue, bone, and joint infections caused by susceptible bacteria
Therapy for infectious diarrhea including traveler’s diarrhea and enteric fever
Treatment of prostatitis and gonorrhea
Management of intra-abdominal infections in combination with anaerobic coverage (e.g., with metronidazole)
Post-exposure prophylaxis and treatment of inhalational anthrax
Treatment and prevention of plague caused by Yersinia pestis
Used in complicated intra-abdominal infections and soft tissue infections when other antibiotics are unsuitable
Treatment of bone and joint infections such as osteomyelitis
Management of cystic fibrosis-associated Pseudomonas infections
Empiric therapy in neutropenic fever and febrile immunocompromised patients
Treatment of certain sexually transmitted infections (e.g., gonorrhea)
Therapy for typhoid and paratyphoid fever
Alternative agent for susceptible multidrug-resistant bacterial infections

Side Or Adverse Effects

Tendinopathy including tendonitis and tendon rupture, especially Achilles tendon
Peripheral neuropathy presenting as numbness, tingling, or burning pain; potential for permanent nerve damage
Central nervous system effects including headache, dizziness, confusion, agitation, paranoia, hallucinations, and suicidal ideation
Gastrointestinal disturbances: nausea, vomiting, diarrhea, abdominal pain
Photosensitivity reactions leading to increased risk of sunburn and skin rash
Hypoglycemia or hyperglycemia, particularly in diabetic patients; risk of severe low blood sugar leading to coma
QT interval prolongation and risk of serious cardiac arrhythmias
Serious allergic reactions including anaphylaxis, Stevens-Johnson syndrome, and toxic epidermal necrolysis
Hepatotoxicity manifesting as elevated liver enzymes and, rarely, jaundice
Increased intracranial pressure (pseudotumor cerebri) with symptoms of headache, visual disturbances, and tinnitus
Arthralgia and joint swelling, particularly in pediatric and elderly populations
Potential exacerbation of myasthenia gravis with muscle weakness
Rare cases of aortic aneurysm or dissection with fatal bleeding
Changes in taste and dizziness impacting quality of life
Diarrhea possibly related to Clostridioides difficile infection

Precautions

Use cautiously in patients with history of tendon disorders or elderly patients at increased risk of tendon rupture
Avoid use in patients with known hypersensitivity to fluoroquinolones to prevent severe allergic reactions
Administer with caution in patients with myasthenia gravis due to potential exacerbation of muscle weakness
Monitor blood glucose closely in diabetic patients due to risks of hypo- or hyperglycemia
Avoid concomitant use with drugs known to prolong QT interval or patients with congenital long QT syndrome
Maintain adequate hydration during therapy to reduce risk of crystalluria and renal toxicity
Advise patients to avoid excessive exposure to sunlight and use sun protection due to photosensitivity risk
Dose adjustments necessary in patients with severe renal impairment to prevent accumulation
Cautious use in patients with seizure history or CNS disorders due to potential for CNS stimulation
Avoid in pregnancy unless benefits outweigh risks; safety in pediatric patients not well established
Do not use for viral infections to prevent resistance
Avoid administration with multivalent cation-containing products (e.g., antacids, sucralfate) to prevent decreased absorption
Advise patients not to operate heavy machinery or drive until drug effects on CNS are known
Discontinue therapy and seek medical attention if signs of tendon rupture or serious adverse reactions occur
Use cautiously in patients with cardiac, liver, or kidney diseases due to altered pharmacokinetics and increased adverse effect risk

Warnings

Risk of tendinitis and tendon rupture, which can occur during or after treatment completion; highest risk in elderly and concurrent steroid users
May cause irreversible peripheral neuropathy affecting sensory and motor nerves
Associated with serious mood or behavior changes, including hallucinations, paranoia, agitation, and suicidal thoughts even after a single dose
Potential for severe hypoglycemia and resultant loss of consciousness or coma
Rare but serious risk of aortic aneurysm rupture leading to life-threatening bleeding and death
Potential for severe hypersensitivity reactions including anaphylaxis and severe skin reactions (e.g., Stevens-Johnson syndrome)
Risk of QT interval prolongation and torsades de pointes, especially in patients with electrolyte abnormalities or on other QT-prolonging drugs
Not recommended for use in children without medical advice due to risk of musculoskeletal adverse effects
Avoid coadministration with tizanidine due to pronounced hypotensive and sedative effects
May cause increased intracranial pressure or pseudotumor cerebri, presenting as headache, visual changes, or dizziness
Risk of Clostridioides difficile-associated diarrhea; promptly evaluate diarrhea to prevent complications
Discontinue immediately if severe allergic reactions or severe side effects develop
Use only when no safer antibacterial alternatives are available due to safety concerns
May exacerbate muscle weakness in patients with myasthenia gravis
Avoid breastfeeding during treatment and for two days after last dose due to potential infant exposure

Contraindication

Known hypersensitivity to ciprofloxacin or other fluoroquinolones (e.g., levofloxacin, moxifloxacin, norfloxacin, ofloxacin)
Concurrent use with tizanidine due to risk of significant hypotension and CNS depression
History of tendon disorders related to fluoroquinolone use
Patients with myasthenia gravis as ciprofloxacin may worsen muscle weakness
Known QT interval prolongation or patients with familial history of long QT syndrome
Known severe hepatic or renal impairment without appropriate dose adjustment and monitoring
Hypersensitivity to any components of the oral suspension or tablet formulation
Use in pediatric patients for systemic infections is generally contraindicated unless benefits justify risks
Pregnancy when alternatives with established safety profiles are available, due to potential adverse effects
Patients with epilepsy or history of seizures may be contraindicated or require cautious use
Concurrent administration with certain medications that contraindicate fluoroquinolone use due to severe interactions
Known hypersensitivity to additives in specific formulations such as otic or intravenous forms
Severe cardiac arrhythmias without proper precautions
Severe neurological diseases with predisposition to CNS stimulation
Patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency if risk of hemolytic anemia suspected

Drug Interactions

Antacids containing magnesium, aluminum, or calcium, sucralfate, iron, zinc, or multivitamins reduce ciprofloxacin absorption; separate dosing by at least 2-6 hours
Tizanidine coadministration is contraindicated due to risk of excessive hypotension and CNS depression
Class IA and III antiarrhythmics (e.g., quinidine, amiodarone) may increase risk of QT prolongation
Warfarin and other vitamin K antagonists; ciprofloxacin may increase anticoagulant effects and bleeding risk; INR monitoring required
Theophylline metabolism may be inhibited by ciprofloxacin leading to increased plasma concentrations and toxicity
Cyclosporine; potential increased nephrotoxicity when administered with ciprofloxacin
Phenytoin levels may be elevated due to inhibition of metabolism, necessitating serum level monitoring
Probenecid reduces renal tubular secretion of ciprofloxacin leading to increased plasma levels
Nonsteroidal anti-inflammatory drugs (NSAIDs) may increase risk of CNS stimulation and seizures when combined
Oral diabetes agents or insulin may have altered glucose levels; risk of hypoglycemia or hyperglycemia
Steroid concomitant use increases risk of tendon rupture
Caffeine clearance is decreased by ciprofloxacin, leading to increased stimulatory effects
Sildenafil and other phosphodiesterase inhibitors may have increased plasma levels, raising potential for side effects
Methotrexate concentrations may increase leading to enhanced toxicity
Magnesium-containing laxatives should be avoided during therapy to prevent absorption interference

Preparations Of The Drug

Oral immediate-release tablets: 100 mg, 250 mg, 500 mg, 750 mg strength
Oral extended-release tablets (Cipro XR): 500 mg, 1000 mg for once-daily dosing
Oral suspension available in 100 mg/5 mL and 250 mg/5 mL concentrations; must be shaken before use
Intravenous injection formulations for parenteral therapy in hospitalized patients
Otic suspension combined with hydrocortisone (Cipro HC) for bacterial ear infections
Preferred formulations selected based on infection site, severity, and patient tolerability
Generic formulations widely available enhancing cost-effectiveness and accessibility
Suspension formulations not to be administered via feeding tubes
Extended-release formulations provide advantages in compliance for suitable infections
Parenteral formulations allow use in severe infections and patients unable to take oral medications
Combination otic products provide both anti-inflammatory and antibacterial action
All preparations require storage at controlled room temperature, protecting from moisture and freezing
Oral preparations designed for convenient dosing schedules ensuring therapeutic adherence
Dose forms standardized for use in pediatric, adult, and special patient populations under medical guidance
Pharmaceutical preparations comply with established pharmacopeial standards ensuring quality and efficacy